| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
322.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Witz Pascale |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$54,000 |
D/D |
60,674 |
60,674 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$61,999 |
I/I |
69,662 |
694,387 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$86,000 |
D/D |
96,629 |
1,797,306 |
|
- |
|
| Foletta Mark G |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$64,000 |
D/D |
71,910 |
81,910 |
|
- |
|
| Baltimore David |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$54,000 |
D/D |
60,674 |
60,674 |
|
- |
|
| Wright Timothy Michael |
Chief R & D Officer |
• – – |
2017-07-25 |
4 |
B |
$0.91 |
$250,000 |
D/D |
274,725 |
274,725 |
2.74 |
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2017-07-25 |
4 |
B |
$0.91 |
$200,000 |
D/D |
219,780 |
241,297 |
2.81 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2017-07-25 |
4 |
B |
$0.91 |
$910,000 |
D/D |
1,000,000 |
1,770,677 |
2.39 |
- |
|
| Chevallard Daniel R. |
Chief Financial Officer |
• – – |
2017-07-25 |
4 |
B |
$0.91 |
$50,000 |
D/D |
54,945 |
59,415 |
2.74 |
- |
|
| Rastetter William H |
Director |
– • – |
2017-07-25 |
4 |
B |
$0.91 |
$250,000 |
I/I |
274,725 |
624,625 |
2.1 |
- |
|
| Nea 16 Gp, Llc |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,989,010 |
|
- |
|
| Baskett Forest |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Mott David M |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Makower Joshua |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Makhzoumi Mohamad |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Puttagunta Chetan |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Viswanathan Ravi |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Sakoda Jon |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Florence Anthony A. Jr. |
10% Owner |
– – • |
2017-07-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,989,010 |
|
- |
|
| Chevallard Daniel R. |
Chief Financial OfficerOfficer |
• – – |
2017-05-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,470 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2017-03-22 |
4 |
B |
$1.23 |
$368,100 |
D/D |
300,000 |
700,677 |
2.39 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2017-03-21 |
4 |
B |
$1.20 |
$239,800 |
D/D |
200,000 |
400,677 |
2.39 |
- |
|
341 Records found
|
|
Page 5 of 14 |
|
|
0.04 (1.78%) 
